Cargando…

RNA Expression of DNA Damage Response Genes in Muscle-Invasive Bladder Cancer: Influence on Outcome and Response to Adjuvant Cisplatin-Based Chemotherapy

Background: Perioperative cisplatin-based chemotherapy (CBC) can improve the outcome of patients with muscle-invasive bladder cancer (MIBC), but it is still to be defined which patients benefit. Mutations in DNA damage response genes (DDRG) can predict the response to CBC. The value of DDRG expressi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Herrmann, Jonas, Schmidt, Helena, Nitschke, Katja, Weis, Cleo-Aron, Nuhn, Philipp, von Hardenberg, Jost, Michel, Maurice Stephan, Erben, Philipp, Worst, Thomas Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8073847/ https://www.ncbi.nlm.nih.gov/pubmed/33919527 http://dx.doi.org/10.3390/ijms22084188

Ejemplares similares

Phosphodiesterase SMPDL3B Gene Expression as Independent Outcome Prediction Marker in Localized Prostate Cancer
por: Waldbillig, Frank, et al.
Publicado: (2020)

ANLN and TLE2 in Muscle Invasive Bladder Cancer: A Functional and Clinical Evaluation Based on In Silico and In Vitro Data
por: Wu, Sheng, et al.
Publicado: (2019)

The EEF1A2 gene expression as risk predictor in localized prostate cancer
por: Worst, Thomas Stefan, et al.
Publicado: (2017)

Long noncoding RNA MIR31HG and its splice variants regulate proliferation and migration: prognostic implications for muscle invasive bladder cancer
por: Wu, Sheng, et al.
Publicado: (2020)

miR-10a-5p and miR-29b-3p as Extracellular Vesicle-Associated Prostate Cancer Detection Markers
por: Worst, Thomas Stefan, et al.
Publicado: (2019)

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making
por: Worst, Thomas S., et al.
Publicado: (2018)

Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening
por: Rinaldetti, Sebastien, et al.
Publicado: (2018)

Neuropilin-2 and Its Transcript Variants Correlate with Clinical Outcome in Bladder Cancer
por: Förster, Sarah, et al.
Publicado: (2021)

POFUT1 mRNA expression as an independent prognostic parameter in muscle-invasive bladder cancer
por: Wahby, Sarah, et al.
Publicado: (2020)

FOXM1 predicts disease progression in non-muscle invasive bladder cancer
por: Rinaldetti, Sebastien, et al.
Publicado: (2018)

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes
por: Rinaldetti, Sebastien, et al.
Publicado: (2017)

IL1RN and KRT13 Expression in Bladder Cancer: Association with Pathologic Characteristics and Smoking Status
por: Worst, Thomas S., et al.
Publicado: (2014)

Changes in neutrophile-to-lymphocyte ratio as predictive and prognostic biomarker in metastatic prostate cancer treated with taxane-based chemotherapy
por: Neuberger, Manuel, et al.
Publicado: (2022)

Reinvestigating the clinical relevance of the m(6)A writer METTL3 in urothelial carcinoma of the bladder
por: Koch, Jonas, et al.
Publicado: (2023)

Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer
por: Westhoff, Niklas, et al.
Publicado: (2020)

The Impact of Small Extracellular Vesicles on Lymphoblast Trafficking across the Blood-Cerebrospinal Fluid Barrier In Vitro
por: Erb, Ulrike, et al.
Publicado: (2020)

Subtype specific expression and survival prediction of pivotal lncRNAs in muscle invasive bladder cancer
por: Rinaldetti, Sebastien, et al.
Publicado: (2020)

Systemic inflammatory biomarkers as predictive and prognostic factors in men with metastatic castration-refractory prostate cancer treated with docetaxel therapy: a comprehensive analysis in a German real-world cohort
por: Neuberger, Manuel, et al.
Publicado: (2022)

An m6A-Driven Prognostic Marker Panel for Renal Cell Carcinoma Based on the First Transcriptome-Wide m6A-seq
por: Waldbillig, Frank, et al.
Publicado: (2023)

An Epigenomic Approach to Improving Response to Neoadjuvant Cisplatin Chemotherapy in Bladder Cancer
por: Xylinas, Evanguelos, et al.
Publicado: (2016)

Thymus and autoimmunity
por: Marx, Alexander, et al.
Publicado: (2021)

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer
por: Matsubara, Nobuaki, et al.
Publicado: (2013)

FOXA1 Gene Expression for Defining Molecular Subtypes of Muscle-Invasive Bladder Cancer after Radical Cystectomy
por: Sikic, Danijel, et al.
Publicado: (2020)

Peritoneal flap for lymphocele prophylaxis following robotic-assisted laparoscopic radical prostatectomy with pelvic lymph node dissection: study protocol and trial update for the randomized controlled PELYCAN study
por: Neuberger, M., et al.
Publicado: (2021)

Investigation of Bladder Cancer Cell Response to Cryoablation and Adjunctive Cisplatin Based Cryo/Chemotherapy
por: Santucci, Kimberly L, et al.
Publicado: (2020)

Lipopolysaccharide Tolerance in Human Primary Monocytes and Polarized Macrophages
por: Li, Hui, et al.
Publicado: (2023)

The Prognostic Value of FGFR3 Expression in Patients with T1 Non-Muscle Invasive Bladder Cancer
por: Sikic, Danijel, et al.
Publicado: (2021)

Plasmacytoid variant of bladder cancer defines patients with poor prognosis if treated with cystectomy and adjuvant cisplatin-based chemotherapy
por: Keck, Bastian, et al.
Publicado: (2013)

The comprehensive complication index (CCI): proposal of a new reporting standard for complications in major urological surgery
por: Kowalewski, K. F., et al.
Publicado: (2020)

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer
por: Kriegmair, M.C., et al.
Publicado: (2018)

Platinum Concentration and Pathologic Response to Cisplatin-Based Neoadjuvant Chemotherapy in Muscle-Invasive Bladder Cancer
por: Guancial, Elizabeth A., et al.
Publicado: (2016)

Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes
por: Yamada, Yosuke, et al.
Publicado: (2020)

Pathologic Response Rates of Gemcitabine/Cisplatin versus Methotrexate/Vinblastine/Adriamycin/Cisplatin Neoadjuvant Chemotherapy for Muscle Invasive Urothelial Bladder Cancer
por: Lee, Franklin C., et al.
Publicado: (2013)

The prognostic value of galactosylceramide-sulfotransferase (Gal3ST1) in human renal cell carcinoma
por: Porubsky, Stefan, et al.
Publicado: (2021)

Future climate change shaped by inter-model differences in Atlantic meridional overturning circulation response
por: Bellomo, Katinka, et al.
Publicado: (2021)

Monoprophylaxis With Cephalosporins for Transrectal Prostate Biopsy After the Fluoroquinolone-Era: A Multi-Institutional Comparison of Severe Infectious Complications
por: Wenzel, Mike, et al.
Publicado: (2021)

Do we have biomarkers to predict response to neoadjuvant and adjuvant chemotherapy and immunotherapy in bladder cancer?
por: Wezel, Felix, et al.
Publicado: (2017)

Androgen receptor activity modulates responses to cisplatin treatment in bladder cancer
por: Kashiwagi, Eiji, et al.
Publicado: (2016)

Functional Characterization of Human Induced Pluripotent Stem Cell-Derived Endothelial Cells
por: Fan, Xuehui, et al.
Publicado: (2022)

Forecasting the response to global warming in a heat-sensitive species
por: Brivio, Francesca, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_vli4b4ve9ljq83oh17p3hb9btk